Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Concurrent Chemoradiotherapy

Concurrent Chemoradiotherapy

Concurrent Chemoradiotherapy is a treatment modality that involves the simultaneous administration of chemotherapy and radiotherapy.
This approach is commonly used to treat various types of cancer, including head and neck, lung, and esophageal cancers.
The combination of these therapies can enhance the efficacy of treatment by targeting cancer cells through different mechanisms, leading to imporved outcomes for patients.
Selecting the optimal protocols and products for Concurrent Chemoradiotherapy can be challenging, which is why PubCompare.ai offers a powerful AI-driven platform to help researchers and clinicians easily locate the latest protocols, identify the best options, and streamline their research process.

Most cited protocols related to «Concurrent Chemoradiotherapy»

1
Comprehensive CRC Cohort for Molecular Profiling
Cited 37 times
Fresh-frozen tumor specimens from 293 consecutive CRC patients were retrieved from the tissue banks of the Royal Melbourne Hospital, Western Hospital and Peter MacCallum Cancer Center in Australia, and the H. Lee Moffitt Cancer Center in the United States; individuals who had received preoperative chemo- and/or radiotherapy or for whom tumor-derived total RNA was inadequate for microarray analysis (RIN < 6) were excluded. All patients gave informed consent, and this study was approved by the medical ethics committees of all sites. Patient median age at diagnosis was 67 years (range 26 to 92 years). All specimens were derived from primary carcinomas and were snap-frozen in liquid nitrogen immediately after surgery for storage at −80°C. Cases comprised 44 stage A, 95 stage B, 93 stage C and 61 stage D cancers; 252 were localized to the colon and 40 to the rectum, with one case missing this information. 22 of 94 patients who had stage B disease and 64 of 91 patients who had stage C disease had received standard adjuvant chemotherapy (either single agent 5-fluouracil/capecitabine or 5-fluouracil and oxaliplatin) or postoperative concurrent chemoradiotherapy (50.4 Gy in 28 fractions with concurrent 5-fluorouracil) according to hospital protocols. All patients were assessed annually. For stage B and C patients, follow-up and additional clinical data including patient gender and TNM staging were collected by Biogrid Australia 1 for Australian patients and the Moffitt Cancer Center Tumor Registry for US patients. The median duration of follow-up was 47.8 months (range 0.9 to 118.6 months) for the 140 patients without recurrence, and 19.1 months (range 1.6 to 93.7 months) for the 48 patients with local or distant recurrence. The median follow-up for all 188 patients was 37.2 months (range 0.9 to 118.6 months).
Total RNA was extracted using Trizol reagent (Invitrogen) from CRC samples containing >60% tumor cells. All samples included showed good integrity of 18S and 28S ribosomal bands (RIN > 6) using a 2100 Bioanalyzer (Agilent Technologies). Total RNA was labeled and hybridized to HG-U133Plus2.0 GeneChip arrays (Affymetrix) according to the manufacturer’s instructions. The microarray data on a subset of 174 tumors have been published previously (NCBI Gene Expression Omnibus, GSE5206 and GSE13067).
In addition, published gene expression data were retrieved for 42 stage A CRCs, 83 stage B, 73 stage C and 62 stage D CRCs analyzed as part of the Expression Project for Oncology (expO) 2 using HG-U133Plus2.0 GeneChip arrays (Affymetrix) (Supplementary Table S1). Of the 62 stage D CRCs, 32 were primary cancer and 30 were metastectomy specimens. None of the primary cancer patients had received preoperative therapy, but 17 metastectomy specimens were from patients who had received adjuvant chemotherapy treatment prior to resection. Data processing and analysis were performed using the statistical software package R (15 ) and appropriate Bioconductor packages (16 (link)).
Jorissen R.N., Gibbs P., Christie M., Prakash S., Lipton L., Desai J., Kerr D., Aaltonen L.A., Arango D., Kruhøffer M., Ørntoft T.F., Andersen C.L., Gruidl M., Kamath V.P., Eschrich S., Yeatman T.J, & Sieber O.M. (2009). Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes’ stage B and C colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(24), 7642-7651.
Publication 2009
Calcibiotic Root Canal Sealer Capecitabine Carcinoma Cells Chemotherapy, Adjuvant Colon Concurrent Chemoradiotherapy Diagnosis Ethics Committees Fluorouracil Freezing Gender Gene Chips Gene Expression Malignant Neoplasms Microarray Analysis Neoadjuvant Therapy Neoplasms Nitrogen Operative Surgical Procedures Oxaliplatin Patients Pharmaceutical Adjuvants Pharmacotherapy Radiotherapy Rectum Recurrence Ribosomes RNA, Neoplasm trizol
2
Comparing PSPT and IMRT Toxicity for NSCLC
Cited 8 times
This trial was designed to compare the toxicity and effectiveness of PSPT with that of standard IMRT, both with concurrent chemotherapy, for patients with locally advanced NSCLC (Appendix: Protocol). Patients were treated at The University of Texas MD Anderson Cancer Center and at Massachusetts General Hospital. The protocol was approved by the institutional review boards of both institutions, and all enrollees provided written informed consent to participate.
Eligibility criteria included age >18 years, Karnofsky Performance Status score ≥70, stage II–IIIB disease, or stage IV disease with a single brain metastasis, or recurrent tumor after surgical resection that could be treated definitively with concurrent chemoradiation, and baseline pulmonary function of forced expiratory volume in the first second of ≥1 liter. Patients who had received systemic chemotherapy regardless of response before enrollment were also eligible. Eligible patients consented to participate after they were evaluated and deemed suitable candidates for concurrent chemoradiation.
The primary endpoint was the first occurrence of either severe (grade ≥3) RP or local failure (LF). The choice to use two primary endpoints emphasized the importance of being free of RP, a potentially lethal form of toxicity, in addition to local disease control. From our historical data13 ,14 (link) we assumed 15% RP rates at 1 year in the IMRT group and 5% in the PSPT group; we further assumed a 25% LF rate in both groups (because the prescribed dose to tumor was the same in both arms by design). With a maximum of 150 randomized and evaluable patients, we would have 81% power to detect such a difference with a one-sided type I error rate of ≥10%. The posterior probability of PSPT being better than IMRT based on the primary endpoints was to be reported. The Bayesian adaptive design was constructed to possess the desirable frequentist properties. Detailed information on assumptions for the study design and trial operating characteristics can be found in the study protocol (Appendix: Protocol).
Liao Z., Lee J.J., Komaki R., Gomez D.R., O’Reilly M.S., Fossella F.V., Blumenschein GR J.r., Heymach J.V., Vaporciyan A.A., Swisher S.G., Allen P.K., Choi N.C., DeLaney T.F., Hahn S.M., Cox J.D., Lu C.S, & Mohan R. (2018). Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 36(18), 1813-1822.
Publication 2018
Acclimatization Arm, Upper Brain Metastases Concurrent Chemoradiotherapy Eligibility Determination Ethics Committees, Research Lung Malignant Neoplasms Neoplasms Non-Small Cell Lung Carcinoma Operative Surgical Procedures Patients Pharmacotherapy Radiotherapy, Intensity-Modulated Volumes, Forced Expiratory
3
Esophageal Cancer Adjuvant Therapy Strategies
Cited 7 times
The eligibility criteria for this study were as follows: patients had undergone radical esophagectomy with 3-field lymph node dissection and were pathologically confirmed with stage II ⁄ III thoracic ESCC; Liver and kidney function and results of blood tests were normal. Heart and lung function were not obviously damaged, and patients were supposed to be able to tolerate chemotherapy; Eastern Cooperative Oncology Group performance status <2. The exclusion criteria were as follows: patients with preoperative chemotherapy or preoperative radiotherapy; with a type of esophageal cancer other than squamous cell carcinoma (SCC) or with cancer at other site; with a history of cancer at any other site; and those lost to follow-up.
According to the type of postoperative adjuvant treatments, patients were classified into three groups: surgery alone (Group S), adjuvant chemotherapy alone (Group CT) and postoperative concurrent chemoradiotherapy (Group CRT). This study was approved by the Institutional Review Board and performed at the 1st Affiliated Hospital of Wenzhou Medical University. The informed consents from all the patients were obtained.
Li L., Zhao L., Lin B., Su H., Su M., Xie D., Jin X, & Xie C. (2017). Adjuvant Therapeutic Modalities Following Three-field Lymph Node Dissection for Stage II/III Esophageal Squamous Cell Carcinoma. Journal of Cancer, 8(11), 2051-2059.
Publication 2017
Chemotherapy, Adjuvant Concurrent Chemoradiotherapy Eligibility Determination Esophageal Cancer Esophagectomy Ethics Committees, Research Heart Hematologic Tests Kidney Liver Lymph Node Excision Malignant Neoplasms Neoplasms Operative Surgical Procedures Patients Pharmaceutical Adjuvants Pharmacotherapy Radiotherapy Respiratory Physiology Squamous Cell Carcinoma
4
Randomized Trial of Chemoradiotherapy vs Surgery for Esophageal Cancer
Cited 6 times
On the basis of our phase II study,15 (link) sample size calculations were made assuming a projected median survival of 56 months for patients assigned to group CRT and 39 months for those assigned to group S. With a two-sided type I error of 0.05 and a power of 80%, a randomization ratio of 1:1 between the experimental and control arms, 7 years of accrual, 2 years of follow-up, and two planned interim analyses, and with a 10% dropout rate taken into account, the intended number of randomly assigned patients was 430 (215 per arm). This study was powered to detect a two-sided 5% significance level hazard ratio (HR) of 0.72. The calculations were performed assuming exponential distribution.
All patients randomly assigned to a group (the intention-to-treat population) were included in the primary evaluation of OS. The per-protocol population was defined as all patients who received surgery. We included the per-protocol population in the analysis of postoperative complications. Only the patients who achieved R0 resection were included in the assessment of DFS. We included patients who received concurrent chemoradiotherapy in the analysis for toxicity of chemotherapy and radiotherapy.
OS and DFS were calculated using the Kaplan-Meier method and were then compared by the log-rank test. The rate of R0 resection, incidence of complications, and peritreatment mortality were compared with the χ2 test or Fisher’s exact test, if indicated. Univariate and multivariate analysis with the Cox proportional hazards model was used to investigate the effect of different factors on survival. Covariates included treatment, age (≤ 60 years v > 60 years), sex, tumor location, clinical T stage (T1 to T2 v T3 v T4) and clinical N stage (Appendix Fig A1, online only). We also used the Cox proportional hazards model to calculate HRs and 95% CIs. We performed two formal interim analyses on Jun 1, 2011, and Dec 31, 2015, after 123 and 451 patients had been enrolled. The significance threshold was defined by the O'Brien-Fleming type boundary 0.000527 in the first interim analysis, 0.014 in the second interim analysis, and 0.045 for the final analysis. The data cutoff for the analysis presented here was December 31, 2016. This trial is registered at ClinicalTrials.gov.
Yang H., Liu H., Chen Y., Zhu C., Fang W., Yu Z., Mao W., Xiang J., Han Y., Chen Z., Yang H., Wang J., Pang Q., Zheng X., Yang H., Li T., Lordick F., D’Journo X.B., Cerfolio R.J., Korst R.J., Novoa N.M., Swanson S.J., Brunelli A., Ismail M., Fernando H.C., Zhang X., Li Q., Wang G., Chen B., Mao T., Kong M., Guo X., Lin T., Liu M, & Fu J. (2018). Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. Journal of Clinical Oncology, 36(27), 2796-2803.
Full text: Click here
Publication 2018
Concurrent Chemoradiotherapy Neoplasms by Site Operative Surgical Procedures Patients Pharmacotherapy Postoperative Complications Radiotherapy
5
Toripalimab for Recurrent Metastatic NPC
Cited 4 times
This study is the NPC cohort from a phase Ib/II, multicohort trial (ClinicalTrials.gov identifier: NCT02915432) evaluating the safety and clinical activity of toripalimab in patients with RM-NPC, head and neck cancer, gastric cancer, and esophageal cancer. The study Protocol was approved by institutional ethics committees of all participating centers. This study was conducted in accordance with the Declaration of Helsinki and the international standards of good clinical practice.
Key eligibility criteria included histologically or cytologically documented RM-NPC refractory to prior standard chemotherapy, or disease progression within 6 months after adjuvant chemotherapy or chemoradiotherapy, age 18 years or older, measurable disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. Key exclusion criteria included anticancer monoclonal antibody therapy within 4 weeks before treatment initiation, any anticancer therapy within 2 weeks before treatment initiation, prior ICI treatment, systemic corticosteroid therapy within 7 days before treatment initiation, known additional malignancies, and active CNS metastases.
The definition of patient population with at least two prior lines (2L+) of systemic chemotherapy included: (1) received at least two lines of systemic chemotherapy; (2) first-line chemotherapy must include platinum-based regimen; (3) neoadjuvant, adjuvant, or concurrent chemoradiotherapy were considered as a line of systemic treatment if tumor recurrence or metastasis occurred within 6 months after the end of neoadjuvant, adjuvant, or concurrent chemotherapy; (4) stage IVb at enrollment as defined by Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, seventh edition; (5) clear evidence of disease progression to prior therapy at enrollment. Intolerance to chemotherapy should not be counted as a line of systemic treatment.
Wang F.H., Wei X.L., Feng J., Li Q., Xu N., Hu X.C., Liao W., Jiang Y., Lin X.Y., Zhang Q.Y., Yuan X.L., Huang H.X., Chen Y., Dai G.H., Shi J.H., Shen L., Yang S.J., Shu Y.Q., Liu Y.P., Wang W., Wu H., Feng H., Yao S, & Xu R.H. (2021). Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). Journal of Clinical Oncology, 39(7), 704-712.
Full text: Click here
Publication 2021
Adrenal Cortex Hormones Cancer of Head and Neck Chemoradiotherapy Chemotherapy, Adjuvant Concurrent Chemoradiotherapy Disease Progression Eligibility Determination Esophageal Cancer Gastric Cancer Institutional Ethics Committees Joints Malignant Neoplasms Monoclonal Antibodies Neoadjuvant Therapy Neoplasm Metastasis Neoplasms Patients Pharmaceutical Adjuvants Pharmacotherapy Platinum Recurrence Safety toripalimab Treatment Protocols

Most recents protocols related to «Concurrent Chemoradiotherapy»

1
Cervical Cancer Diagnosis Protocol
In this study, patients with cervical cancer and healthy controls who were admitted to the hospital from February 2022 to June 2022 were collected. The choice was taken and the informed permission was signed by the patients and their families. Following admission, the patient’s conditions and the progress of the study were fully disclosed to them as well as to their families. The Zhengzhou University First Affiliated Hospital Ethics Committee has authorized this work (2022-KY-1341-002). The eligibility criteria are as follows: (1) Age: 18-72 years old; (2) All patients with cervical cancer were pathologically diagnosed; All healthy controls underwent detailed CT, MRI, and other imaging examinations. (3) All patients had not received pelvic and systemic concurrent chemoradiotherapy before admission, and the main organ functions were normal. (4) None of the participants had antibiotics administration 3 months before samples collection. And the two groups were matched by age and body mass index (BMI).
Chang L., Qiu L., Lei N., Zhou J., Guo R., Gao F., Dong S., Chen M., Wu F, & Qin B. (2023). Characterization of fecal microbiota in cervical cancer patients associated with tumor stage and prognosis. Frontiers in Cellular and Infection Microbiology, 13, 1145950.
Full text: Click here
Publication 2023
Antibiotics, Antitubercular Cervical Cancer Concurrent Chemoradiotherapy Eligibility Determination Ethics Committees, Clinical Index, Body Mass Patients Pelvis Physical Examination Specimen Collection
2
Atezolizumab in Extensive-Stage SCLC
We collected data from all patients treated with first-line atezolizumab, etoposide, and carboplatin from the tumor registry at Pusan National University Hospital, Busan, South Korea (atezolizumab group) from April 2020. Furthermore, we analyzed the data obtained from a cohort of patients with ES-SCLC treated with chemotherapy alone (chemo-only group) between January 2018 and March 2020. Eligible patients included those who had been diagnosed with ES-SCLC in accordance with the Veterans Administration Lung Cancer Study Group. Patients with previous definitive concurrent chemoradiation therapy for limited-stage SCLC were also excluded. The study protocol was approved by the Institutional Review Board (IRB) of Pusan National University Hospital (IRB no. 2208-016-118). Moreover, the study was conducted in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived by the IRB of Pusan National University Hospital because of the retrospective nature of the study, and the analysis used anonymous clinical data.
Kim S.H., Jo E.J., Mok J., Lee K., Kim K.U., Park H.K., Lee M.K., Eom J.S, & Kim M.H. (2023). Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer. The Korean Journal of Internal Medicine, 38(2), 218-225.
Publication 2023
atezolizumab Carboplatin Concurrent Chemoradiotherapy Ethics Committees, Research Etoposide Lung Cancer Neoplasms Patients Pharmacotherapy Small Cell Lung Carcinoma Therapeutics
3
Adverse Reactions in nCRT for Cancer
A variety of nCRT-related adverse reactions were evaluated, including bone marrow suppression, radioactive proctitis, intestinal obstruction or perforation, narrow lumen, anastomotic fistula, perianal skin injury, emesis, and hand-foot syndrome. Hand-foot syndrome was mainly associated with capecitabine treatment. During concurrent chemoradiotherapy, blood routine examinations and biochemical examinations were conducted weekly. RTOG radiation injury classification and Common Terminology Criteria for Adverse Events (CTCAE, Version 5) were adopted to assess adverse events. Grades 1 and 2 myelosuppression were considered mild, while grades 3 and 4 were considered moderate to severe. Similarly, grades 1 and 2 were defined as mild radiation proctitis, and grades 3 and 4 were defined as moderate to severe radiation proctitis. The remaining adverse reactions including intestinal obstruction or perforation, narrow lumen, anastomotic fistula, perianal skin injury, emesis, and hand-foot syndrome were evaluated by their occurrence or not.
Xu Y., Zou H., Shao Z., Zhang X., Ren X., He H., Zhang D., Du D, & Zou C. (2023). Efficacy and safety of different radiotherapy doses in neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: A retrospective study. Frontiers in Oncology, 13, 1119323.
Full text: Click here
Publication 2023
BLOOD Bone Marrow Capecitabine Concurrent Chemoradiotherapy Fistula Hand-Foot Syndrome Injuries Intestinal Obstruction Physical Examination Proctitis Radiation Injury Radioactivity Radiotherapy Skin Surgical Anastomoses Vomiting
4
Anlotinib and Temozolomide for Recurrent Glioblastoma
A retrospective analysis was made of 26 patients who were newly diagnosed or had recurrent high-grade glioma treated in the Department of Radiotherapy of Jinling Hospital from 2017 to 2022.
Inclusion criteria: 1) Karnofsky Performance Scale (KPS) ≥60; 2) age ≥ 18 years old; 3) pathologically confirmed as World Health Organization Level IV glioblastoma (GBM); 4) recurrence after magnetic resonance imaging (MRI) review (including MR spectroscopy (MRS) and perfusion imaging) is assessed by surgeons, radiologists, and oncologists according to Response Assessment in Neuro-Oncology (RANO) criteria; 5) measurable lesions; 6) good bone marrow, liver, and kidney functions; 7) anlotinib combined with dose-intensive temozolomide (TMZ) in the treatment of relapse; 8) previous standard concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy (AC).
Exclusion criteria: 1) complications of other malignant tumors or serious diseases; 2) patients with hypertension whose blood pressure still cannot be reduced to the normal range after treatment with antihypertensive drugs, patients with grade I and above myocardial ischemia or myocardial infarction, and arrhythmias (including QT interval ≥440 ms), patients with grade II cardiac insufficiency, and patients with arteriovenous thrombosis, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, and pulmonary embolism within 6 months; 3) lack of follow-up data.
All the patients were younger than 75 years old and their KPS scores were above 60 points. Anlotinib was taken orally during postoperative concurrent chemoradiotherapy or after relapse. It was used as 12 mg once a day for 2 weeks and stopped for 1 week. Efficacy was evaluated according to the RANO criteria, and the cranial MR examination was conducted every 1–3 months. According to the MR results and clinical symptoms, the efficacy was divided into complete remission (CR), partial response (PR), stable disease (SD), and progressive disease (PD). The overall response rate (ORR) means CR and PR. The DCR means CR, PR, and SD. The primary study endpoints were PFS at 6 months and OS at 1 year (both were calculated at the start of anlotinib treatment).
Shen F., Li J., Liu F., Sun N., Qiu X., Ding W, & Sun X. (2023). The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis. Frontiers in Oncology, 13, 1095362.
Full text: Click here
Publication 2023
Aftercare anlotinib Antihypertensive Agents Blood Pressure Bone Marrow Cardiac Arrhythmia Cerebrovascular Accident Chemotherapy, Adjuvant Concurrent Chemoradiotherapy Cranium Deep Vein Thrombosis Glioblastoma Heart Failure High Blood Pressures Kidney Liver Magnetic Resonance Spectroscopy Malignant Glioma Malignant Neoplasms Myocardial Infarction Myocardial Ischemia Neoplasms Oncologists Patients Pulmonary Embolism Radiologist Radiotherapy Recurrence Relapse Surgeons Temozolomide Thrombosis Transient Ischemic Attack Youth
5
Radiotherapy for Locally Advanced Cervical Cancer
This study was approved by the Institutional Review Board, and written informed consent requirement was waived. Totally, 104 patients with pathologically diagnosed LACC between July 2017 and December 2021 were retrospectively enrolled. For all participants, the inclusion criteria were as follows: (1) patients who pathologically confirmed LACC; (2) patients who underwent radiotherapy as the main treatment; (3) patients who underwent both CT and MR examinations within three weeks before radiotherapy. The exclusion criteria were as follows: (1) external irradiation treatment was interrupted for more than one month; (2) the radiation dose to tumor was less than 80Gy; (3) surgery was performed before radiotherapy. All enrolled participants with matched multi-modality data were randomly divided into training and testing cohorts at a ratio of 2: 1 to develop and assess the network, respectively.
Recurrent tumors were classified into local, regional, or distant progressive tumors after concurrent chemoradiotherapy was completed. Clinical follow-up exams of the patients were performed every 3 months until 36 months. Physical examination and tumor markers were checked. Imaging examination of pelvic MRI (CT for special patients) was performed when suspected of recurrence and the biopsy was performed for confirmation.
The clinicopathologic data of all enrolled patients, including age, tumor stage (FIGO 20091), pathologic diagnosis, lymph node status and dose of radiotherapy, were obtained from medical records for statistical analysis and the recurrence status of all patients was also followed up.
Wang J., Mao Y., Gao X, & Zhang Y. (2023). Recurrence risk stratification for locally advanced cervical cancer using multi-modality transformer network. Frontiers in Oncology, 13, 1100087.
Full text: Click here
Publication 2023
Biopsy Concurrent Chemoradiotherapy Diagnosis Ethics Committees, Research Neoplasms Nodes, Lymph Operative Surgical Procedures Patients Pelvic Examination Physical Examination Radiotherapy Recurrence Tumor Markers

Top products related to «Concurrent Chemoradiotherapy»

1
Pinnacle3 treatment planning system by Philips
Sourced in United States
The Pinnacle3 treatment planning system is a software application developed by Philips for use in radiation therapy. It provides tools for creating and optimizing treatment plans for cancer patients undergoing radiation therapy. The core function of the Pinnacle3 system is to assist healthcare professionals in the planning and delivery of radiation treatments.
2
Tim trio by Siemens
Sourced in Germany, United States, United Kingdom, China
The Tim Trio is a versatile laboratory equipment that serves as a temperature-controlled magnetic stirrer. It features three independent stirring positions, allowing simultaneous operation of multiple samples. The device maintains a consistent temperature range to ensure accurate and reliable results during experimental procedures.
3
Spss software version 24 by IBM
Sourced in United States, Japan, United Kingdom, India
SPSS software version 24.0 is a statistical analysis and data management software package developed by IBM. It provides a range of tools for data analysis, including descriptive statistics, bivariate statistics, prediction for numerical outcomes, and prediction for identifying groups. The software is designed to help users analyze and understand complex data sets.
4
Sterile sp tube by Eiken Chemical
Sourced in Japan
The Sterile SP tube is a laboratory equipment used for the collection and storage of biological samples. It is designed to maintain the sterility of the contents, ensuring the integrity of the samples during handling and transportation.
5
Discovery 750w by GE Healthcare
Sourced in United States
The Discovery 750w is a versatile lab equipment product from GE Healthcare. It is designed to perform a range of analytical tasks within the laboratory environment. The core function of the Discovery 750w is to provide reliable and accurate measurements and analysis of samples.
6
Nylon cell strainer by BD
Sourced in United States, Germany, United Kingdom, Canada
The Nylon cell strainer is a laboratory equipment designed to separate cells or other particles from a liquid suspension. It features a nylon mesh screen that filters the liquid, trapping the desired cells or particles while allowing the rest of the liquid to pass through. The strainer's core function is to facilitate the isolation and purification of specific cell types or other biological components from complex mixtures.
7
Brilliance big bore by Philips
Sourced in United States, Netherlands
The Philips Brilliance Big Bore is a computed tomography (CT) imaging system designed for diagnostic and treatment planning purposes. It features a large bore size, allowing for the scanning of a wide range of patient sizes and body types. The system provides high-quality images to support clinical decision-making.
8
Pinnacle planning system by Philips
Sourced in United States
The Pinnacle planning system is a medical imaging software solution developed by Philips. It is designed to assist healthcare professionals in the planning and management of radiation therapy treatments. The system provides tools for importing, visualizing, and analyzing patient data from various imaging modalities, enabling healthcare providers to develop customized treatment plans.
9
Duragesic by Johnson & Johnson
Sourced in China, Belgium
Duragesic is a transdermal patch that delivers a continuous and controlled release of the opioid analgesic fentanyl through the skin. The patch is designed to provide long-acting pain relief for opioid-tolerant patients.
10
Spss v19 by IBM
Sourced in United States, Japan, Germany, China, United Kingdom
SPSS v19.0 is a statistical software package developed by IBM. It provides a range of data analysis and management capabilities, including data manipulation, statistical modeling, and visualization tools. The software is designed to assist users in analyzing and interpreting data, but a detailed description of its core function is not available while maintaining an unbiased and factual approach.

More about "Concurrent Chemoradiotherapy"